Friedrich Miescher Institute for Biomedical Research

Incyte Pharmaceuticals, Inc.

Denis Monard

Ludger Altrogge

Karel Gerrit Odink

Bérengère Fayard

Ulrich Hengst

Hugo Albrecht

Sergio Gloor

The present invention relates to a method of inhibiting metastasis comprising the administration of an inhibitor of protease nexin-1 (PN-1), characterized in that said inhibitor is administered at a therapeutical dosage that does not completely inhibit the expression and/or activity of PN-1.

Use of protease nexin 1 inhibitors to reduce metastasis

There is provided a method of identifying a PAR cleaving molecule comprising the steps of: (a) providing an immobilized PAR cleavage peptide linked to a reporter molecule; (b) contacting the immobilized PAR cleavage peptide with a PAR cleaving molecule; and (c) detecting release of the reporter molecule.

Protease-activated receptor (par) modulator assays

There is provided a protease inhibitor and a method of inhibiting a protease selected from the group consisting of thrombin, chymotrypsin and neuropsin, by contacting the protease with an effective amount of a member of the phosphoethanolamine binding protein (PEBP) family.

Methods and reagents for protease inhibition

The invention relates to a neurite-promoting factor released by glial cells, to related proteins and fragments thereof retaining their neurite-promoting activity, to DNAs coding for the amino acid sequence of the neurite-promoting factor and fragments thereof, to hybrid vectors containing such DNAs, to hosts transformed with such a hybrid vector, to processes for the preparation of the DNAs, vectors and transformed hosts, to processes for the manufacture of the neurite-promoting factor, related proteins and its fragments, and to their use in the treatment of lesions in the nervous system.

Growing community of inventors

Füllinsdorf, Switzerland

Denis Monard